Amarin Corp Plc\uk.
- AMRN · Nasdaq
- Pharmaceutical Preparations
- Dublin 2, Ireland
- CIK 0000897448
Updated from SEC filings through
Top things to know
Executives
-
Aaron Berg President & Chief Executive Officer 8-K, October 28, 2026 -
Peter Fishman Amarin’s Chief Financial Officer 8-K, October 28, 2026 -
Jonathan Provoost EVP, Chief Legal Officer Form 4, July 15, 2026 - David Paul Keenan EVP, Chief Operating Officer Form 4, July 15, 2026
- Steven B. Ketchum EVP, Chief Scientific Officer Form 4, July 15, 2026
What leadership is saying
“Our results in the third quarter demonstrate the continued positive trajectory in our operational, financial and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IPE) franchise and deliver long-term shareholder value”
Earnings press release (8-K Ex. 99.1), filed October 28, 2026
Amarin Corp Plc\uk is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Dublin 2, Ireland. It trades as AMRN on Nasdaq. Revenue was $214M in the fiscal year ending December 31, 2025, -6.5% from the year before.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $214M 10-K, 2026-03-02 | $229M 10-K, 2026-03-02 | $307M 10-K, 2026-03-02 | $369M 10-K, 2025-03-12 | $583M 10-K, 2024-02-29 |
| Operating income | -$50.2M 10-K, 2026-03-02 | -$91.8M 10-K, 2026-03-02 | -$67.6M 10-K, 2026-03-02 | -$106M 10-K, 2025-03-12 | $10.5M 10-K, 2024-02-29 |
| SG&A | $115M 10-K, 2026-03-02 | $152M 10-K, 2026-03-02 | $200M 10-K, 2026-03-02 | $304M 10-K, 2025-03-12 | $408M 10-K, 2024-02-29 |
| Net income | -$38.8M 10-K, 2026-03-02 | -$82.2M 10-K, 2026-03-02 | -$59.1M 10-K, 2026-03-02 | -$106M 10-K, 2025-03-12 | $7.7M 10-K, 2024-02-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | President & Chief Executive Officer | 8-K, October 28, 2026 |
| | Amarin’s Chief Financial Officer | 8-K, October 28, 2026 |
| Executive Vice President, Chief Legal & Compliance Officer, Corporate Secretary at Amarin Corp. | EVP, Chief Legal Officer | Form 4, July 15, 2026 |
| David Paul Keenan | EVP, Chief Operating Officer | Form 4, July 15, 2026 |
| Steven B. Ketchum | EVP, Chief Scientific Officer | Form 4, July 15, 2026 |
| Diane E. Sullivan | Director | 10-K, March 2, 2026 |
| Keith L. Horn | Director | 10-K, March 2, 2026 |
| Louis Sterling III. | Director | 10-K, March 2, 2026 |
| Michael Torok | Director | 10-K, March 2, 2026 |
| Odysseas Kostas, M.D. | Director | 10-K, March 2, 2026 |
| Oliver O'Connor | Director | 10-K, March 2, 2026 |
| Patrice Bonfiglio | Director | 10-K, March 2, 2026 |
| Paul Cohen, M.D. | Director | 10-K, March 2, 2026 |
Shares and governance
| Shares outstanding | 380,694 (as of February 20, 2013) | 10-K, February 28, 2013 |
|---|---|---|
| Public float | $335M (as of June 30, 2025) | 10-K, March 2, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 28, 2026 |
| Latest proxy statement | Meeting April 10, 2026 (filed April 10, 2026) | DEF 14A, April 10, 2026 |
| Auditor | Ernst & Young LLP (Iselin, New Jersey) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-11-18
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-10-28
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-15
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-27
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-02-25
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-22
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Amarin Corp Plc\uk
- What does Amarin Corp Plc\uk do?
- Amarin Corp Plc\uk is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in Dublin 2, Ireland.
- What is Amarin Corp Plc\uk's revenue?
- $214M for the fiscal year ending December 31, 2025, from its 10-K filed March 2, 2026.
- Is Amarin Corp Plc\uk profitable?
- Amarin Corp Plc\uk reported net income of -$38.8M for the fiscal year ending December 31, 2025.
- Who is the CFO of Amarin Corp Plc\uk?
- Peter Fishman, Amarin’s Chief Financial Officer, as named in a 8-K filed October 28, 2026.
- Where is Amarin Corp Plc\uk headquartered?
- Dublin 2, Ireland.
- What is Amarin Corp Plc\uk's stock ticker?
- AMRN on Nasdaq.
- What industry is Amarin Corp Plc\uk in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Amarin Corp Plc\uk's website?
- amarincorp.com.
- When does Amarin Corp Plc\uk report earnings next?
- January 20, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Amarin Corp Plc\uk a public company?
- Yes. Amarin Corp Plc\uk files with the SEC under CIK 0000897448 and trades as AMRN.
- Who audits Amarin Corp Plc\uk?
- Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
- How many shares of Amarin Corp Plc\uk are outstanding?
- 380,694 shares as of February 20, 2013, from its 10-K filed February 28, 2013.
- What is Amarin Corp Plc\uk's public float?
- $335M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
- How many business segments does Amarin Corp Plc\uk report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 28, 2026.
- When is Amarin Corp Plc\uk's annual shareholder meeting?
- April 10, 2026, per its proxy statement (DEF 14A) filed April 10, 2026.